Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medipal HoldingsMEPDF 81 Revenue per Share is $121.93 as of Mar. 2026. GuruFocus rates MEPDF with a GF Score™ of 81/100 and a GF Value™ of $17.73 (Fairly Valued). The stock has 3 warning signs investors should review. Among 113 Medical Distribution companies, Medipal Holdings ranks better than 56.64% on this metric.
Medipal Holdings's revenue per share for the
three
months ended in Mar. 2026 was $27.73.
Medipal Holdings's revenue per share for the trailing twelve months (TTM) ended in Mar. 2026 was $121.93.
Good Sign:
Medipal Holdings Corp has shown predictable revenue and earnings growth.
During the past 12 months, the average Revenue Per Share Growth Rate of Medipal Holdings was 5.30% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was 6.10% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was 5.60% per year.
During the past 10 years, the average Revenue Per Share Growth Rate was 3.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Medipal Holdings's Revenue per Share or its related term are showing as below:
MEPDF'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0.2 Med: 4.4 Max: 6.2
Current: 6.1
During the past 13 years, Medipal Holdings's highest 3-Year average Revenue Per Share Growth Rate was 6.20% per year. The lowest was 0.20% per year. And the median was 4.40% per year.
MEPDF's 3-Year Revenue Growth Rate is ranked better than 56.64% of 113
companies
in the Medical Distribution industry
Industry Median: 4.7
vs MEPDF: 6.10
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Medipal Holdings Revenue per Share Related Terms
Medipal Holdings Revenue per Share Historical Data
* Premium members only.
The historical data trend for Medipal Holdings's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEPDF vs MCK, COR, CAH: Revenue per Share Comparison
For the Medical Distribution subindustry, Medipal Holdings's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medipal Holdings PS Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Medipal Holdings's PS Ratio distribution charts can be found below:
* The bar in red indicates where Medipal Holdings's PS Ratio falls into.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Medipal Holdings's Revenue Per Share for the fiscal year that ended in Mar. 2026 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $121.93
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medipal Holdings (MEPDF) has a Revenue per Share of $121.93 as of Mar. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on Medipal Holdings and its competitors. According to the industry distribution chart, Medipal Holdings ranks #49 out of 113 companies in the Medical Distribution industry, placing it in the top 43.4%.
Is Medipal Holdings' Revenue per Share too high?
Medipal Holdings' current Revenue per Share is $121.93. The Medical Distribution industry median Revenue per Share is 4.70. Medipal Holdings' value of $121.93 is 2494.3% above this industry median. Based on the distribution chart, Medipal Holdings ranks #49 out of 113 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Medipal Holdings has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Medipal Holdings' Revenue per Share compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Medipal Holdings ranks #49 out of 113 companies for Revenue per Share. This puts Medipal Holdings in the upper half of its industry. The industry median Revenue per Share is 4.70. Medipal Holdings' value of $121.93 is 2494.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Medical Distribution company?
The median Revenue per Share among Medical Distribution companies is 4.70, based on 113 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medipal Holdings's current Revenue per Share of $121.93 is 2494.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Medipal Holdings and its competitors. For the Medical Distribution industry, the median Revenue per Share is 4.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medipal Holdings's current Revenue per Share is $121.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medipal Holdings stock overvalued right now?
Based on GuruFocus' analysis, Medipal Holdings (MEPDF) is currently considered Fairly Valued. The stock's GF Value™ is $17.73, compared to a current price of $18.35 — trading 3.5% above its estimated fair value. The current Revenue per Share is $121.93 and 2494.3% above the Medical Distribution industry median of 4.70. Medipal Holdings' overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Medipal Holdings (MEPDF), the current Revenue per Share is $121.93 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medipal Holdings (MEPDF) Overvalued in 2026?
Based on GuruFocus' analysis, Medipal Holdings stock appears to be overvalued.
The current stock price of $18.35 is trading 3.5% above its estimated GF Value™ of $17.73.
GuruFocus considers Medipal Holdings to be Fairly Valued.
Key valuation signals for MEPDF:
Revenue per Share: $121.93
GF Value™: $17.73 vs. price of $18.35 (3.5% above fair value)
Industry Position: 2494.3% above the Medical Distribution median (#49 of 113)
No single metric tells the full story. See the MEPDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medipal Holdings Corp is engaged in the wholesale distribution of pharmaceuticals, cosmetics, daily necessities, and related products. The company operates through three reportable segments: Wholesale business of medical drugs; Cosmetics, Daily Necessities and OTC Pharmaceuticals Wholesale Business; and Wholesale of animal medicines and food processing ingredients. The Wholesale business of medical drugs segment targets hospitals, clinics, and dispensing pharmacies; the Cosmetics and OTC segment serves drug stores, home centers, convenience stores, and supermarkets; while the Wholesale of animal medicines and food processing ingredients segment supplies veterinary clinics, livestock and fisheries businesses, and food manufacturers.
81GF Score
Get the complete analysis for MEPDF
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEPDF has been successfully added to your 
